SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, and neurological conditions, today announced the publication of an article, “The emerging role of fatty acid binding protein 7 (FABP7) in cancers,” in Drug Discovery Today, a peer-reviewed journal.

加利福尼亚州索拉纳海滩，2024年4月23日（环球通讯社）--Artelo Biosciences，Inc.（纳斯达克：ARTL），一家临床阶段制药公司，专注于调节脂质信号通路，为患有癌症，疼痛，皮肤病和神经系统疾病的人开发治疗方法，今天宣布在同行评审期刊《今日药物发现》上发表一篇文章，“脂肪酸结合蛋白7（FABP7）在癌症中的新兴作用”。

The article analyzes the results of various studies and presents a comprehensive analysis of FABP7’s role in a variety of cancers and its correlation with patient prognosis, as well as its potential utility as a validated target in cancer treatment..

本文分析了各种研究的结果，并全面分析了FABP7在多种癌症中的作用及其与患者预后的相关性，以及其作为癌症治疗中经过验证的靶标的潜在用途。。

The publication reveals that FABP7, an intracellular protein involved in the uptake, transportation, metabolism, and storage of fatty acids, is upregulated in several cancers including breast, brain, and kidney cancers and is generally associated with a poor patient prognosis. Additionally, the evidence shows that both genetic and pharmacological inhibition of FABP7 led to reduced tumor cell growth, migration, and invasion in multiple studies.

该出版物显示，FABP7是一种参与脂肪酸摄取，运输，代谢和储存的细胞内蛋白，在包括乳腺癌，脑癌和肾癌在内的多种癌症中被上调，通常与患者预后不良有关。此外，证据表明，在多项研究中，FABP7的遗传和药理学抑制均导致肿瘤细胞生长，迁移和侵袭减少。

Moreover, inhibition of FABP7 improved host survival rates, particularly in brain cancers, indicating its role as a novel target in cancer..

此外，抑制FABP7提高了宿主的存活率，特别是在脑癌中，表明其作为癌症新靶点的作用。。

“Artelo is dedicated to furthering research on FABP inhibition including selective- and pan-FABP inhibition, with the aim of providing new therapeutic options for patients battling cancer and other serious conditions,” said Professor Saoirse Elizabeth O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences.

Artelo Biosciences转化科学副总裁Saoirse Elizabeth O'Sullivan教授表示：“Artelo致力于进一步研究FABP抑制，包括选择性和泛FABP抑制，旨在为患有癌症和其他严重疾病的患者提供新的治疗选择。”。

“The insights highlighted in this review continue to underscore the potential impact of our FABP inhibitor platform in several therapeutic areas.”.

“本综述中强调的见解继续强调了我们的FABP抑制剂平台在几个治疗领域的潜在影响。”。

Artelo is currently evaluating multiple compounds for their therapeutic potential from the Company’s extensive FABP inhibitor library. The most advanced of these is ART26.12, a novel, potent and selective inhibitor of FABP5. In preclinical studies, ART26.12 demonstrated positive results in cancer, cancer bone pain, and painful neuropathies such as chemotherapy-induced peripheral neuropathy (CIPN).

Artelo目前正在从该公司广泛的FABP抑制剂库中评估多种化合物的治疗潜力。其中最先进的是ART26.12，一种新型，有效和选择性的FABP5抑制剂。在临床前研究中，ART26.12在癌症，癌症骨痛和疼痛性神经病（如化疗引起的周围神经病（CIPN））中显示出阳性结果。

Artelo plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) during the second quarter of 2024 for the development of ART26.12 in CIPN. Approximately 40% of cancer patients treated with certain chemotherapies will develop neuropathic pain which often requires dose reduction or cessation of anti-cancer treatment and there is currently no FDA-approved therapy to treat or prevent CIPN..

Artelo计划在2024年第二季度向美国食品和药物管理局（FDA）提交一份研究性新药（IND）申请，以在CIPN中开发ART26.12。大约40%接受某些化学疗法治疗的癌症患者会出现神经性疼痛，这通常需要减少剂量或停止抗癌治疗，目前还没有FDA批准的治疗或预防CIPN的疗法。。

For more information about Artelo Biosciences and our commitment to innovative therapies, please visit our website at www.artelobio.com

有关Artelo Biosciences和我们对创新疗法的承诺的更多信息，请访问我们的网站www.artelobio.com

About ART26.12

关于ART26.12

ART26.12, Artelo’s lead Fatty Acid Binding Protein (FABP) inhibitor, is a potent and selective inhibitor of FABP5 being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic, with an initial clinical study planned for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids.

Artelo的铅脂肪酸结合蛋白（FABP）抑制剂ART26.12是一种有效且选择性的FABP5抑制剂，被开发为一种新型的外周作用非阿片类非甾体镇痛药，初步临床研究计划用于化疗诱导的周围神经病变（CIPN）。FABPs是一类细胞内蛋白质，可伴侣脂质，包括内源性大麻素和脂肪酸。

FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. Beyond ART26.12, Artelo’s extensive library of small molecule inhibitors of FABPs have shown therapeutic promise for the treatment of certain cancers, cancer bone pain, neuropathic and nociceptive pain, dermatological and anxiety disorders..

FABP在许多病理学中过度表达并与异常脂质信号传导相关。除了ART26.12之外，Artelo广泛的FABPs小分子抑制剂库已显示出治疗某些癌症，癌症骨痛，神经性和伤害性疼痛，皮肤病和焦虑症的治疗前景。。

About Artelo Biosciences

关于Artelo生物科学

Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation.

Artelo Biosciences，Inc.是一家临床阶段制药公司，致力于开发和商业化调节脂质信号通路的专有疗法。Artelo正在推出一系列广泛适用的候选产品，旨在解决多种疾病和病症（包括厌食症、癌症、焦虑症、疼痛和炎症）中未满足的重大需求。

Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and on X (formerly Twitter): @ArteloBio..

在久经考验的生物制药高管与备受尊敬的研究人员和技术专家的合作下，该公司应用领先的科学，监管和商业学科来开发高冲击疗法。有关更多信息，请访问www.artelobio.com和X（以前的Twitter）：@artelobio。。

Forward Looking Statements

前瞻性声明

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, market opportunity, competitive position, business strategies, potential growth opportunities and other statement that are predictive in nature.

本新闻稿包含《1933年证券法》第27A节、《1934年证券交易法》第21E节和《私人证券诉讼改革法》修订版所指的某些前瞻性声明，包括与公司产品开发、市场机会、竞争地位、业务战略、潜在增长机会和其他预测性声明有关的前瞻性声明。

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms.

这些前瞻性陈述基于当前对我们经营的行业和市场的期望、估计、预测和预测以及管理层当前的信念和假设。这些陈述可以通过使用前瞻性表达来识别，包括但不限于“期望”、“预期”、“打算”、“计划”、“相信”、“估计”、“潜力”、“预测”、“项目”、“应该”、“将会”以及类似的表达和这些术语的否定之处。

These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

这些声明与未来事件有关，涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果、业绩或成就与前瞻性声明中明示或暗示的任何未来结果、业绩或成就存在重大差异。

Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release.

这些因素包括公司向证券交易委员会提交的文件中规定的因素，包括我们未来筹集额外资本的能力。警告潜在投资者不要过度依赖此类前瞻性声明，这些声明仅在本新闻稿发布之日起生效。

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws..

公司没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，适用证券法要求的除外。。

Investor Relations Contact:

投资者关系联系人：

Crescendo Communications, LLC

Crescendo通信有限责任公司

Tel: 212-671-1020

电话：212-671-1020

Email: ARTL@crescendo-ir.com

电子邮件ARTL@crescendo-ir.com